The National Institute On Drug Abuse awards a $300K grant to Acura Pharmaceuticals (NASDAQ: ACUR ) to fund Phase 1 development of the company's Limitx abuse deterrent technology. Under the terms of the grant
Aug 27 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd
Central District of California for an expedited schedule for discovery and a preliminary injunction against Valeant Pharmaceuticals ( VRX +1.4% ) and Pershing Square Capital Management for violating insider trading laws. If successful, the
(Reuters) - Allergan Inc said on Tuesday that it has scheduled a special shareholders meeting for Dec. 18, when activist investor Bill Ackman, who supports a hostile bid for the company by Valeant Pharmaceuticals Inc, will attempt to oust most of its board.
Aug 26 (Reuters) - Allergan Inc said on Tuesday that it has scheduled a special shareholders meeting for Dec. 18, when activist investor Bill Ackman, who supports a hostile bid for the company by Valeant Pharmaceuticals Inc, will attempt to oust most of its board.
business, pharmaceutical companies curb research ..... revenue. Pharmaceuticals fell back ..... could require drug manufacturers to sell drugs ..... force the drug companies to stop using ..... the world. Pharmaceutical companies would reject ..... development of pharmaceuticals or the delivery
In a filing response to the Delaware Chancery Court, Allergan ( AGN +0.3% ) discloses that it has set December 18, 2014 for the special shareholders meeting requested by Valeant Pharmaceuticals ( VRX +1.3% ) and Pershing Square. Post your comment!
By Jason Napodano, CFA : On August 14, 2014, Immune Pharmaceuticals , Inc. (NASDAQ: IMNP ) announced financial results for the second quarter 2014. For the quarter, the company reported no revenues
The initiation of Avanir Pharmaceuticals ' ( AVNR +2% ) AVP-786 clinical trial for MDD triggers a $2M milestone payment to Concert Pharmaceuticals ( CNCE +5.1% ) as part of their license agreement for deuterium-modified dextromethorphan compounds. Post your comment!
Avanir Pharmaceuticals ( AVNR +1% ) initiates a Phase 2 study to evaluate the safety, tolerability and efficacy of AVP-786 for the adjunctive treatment